Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Medicines register
Registers› Irish medicines ›Imigran 20 mg nasal spray, solution
Medicines register · Ireland

Imigran 20 mg nasal spray, solution

Authorisation PA1077/008/004 · GlaxoSmithKline (Ireland) Limited

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 22 Nov 2026
Licence holder
GlaxoSmithKline (Ireland) Limited (all products →)
Active substance
Sumatriptan
Clinical trials
2 clinical trials →
Dosage form
Nasal spray, solution
Route of administration
Nasal use
ATC codes
N02CC, N02CC01
First authorised
07/07/1999
Prescription status
Product subject to prescription which may be renewed (B)
Supply
Supply through pharmacies only
Legal basis
Full application (Article 8(3) of Directive No 2001/83/EC)

Sumatriptan: supply and approvals

12 authorised products on the HPRA list contain Sumatriptan. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 21 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 21 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 21 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 27 years (since 7 July 1999). The HPRA list marks it as marketed in Ireland.

Other medicines with Sumatriptan in Ireland

8 other products on the HPRA list contain Sumatriptan, from 4 licence holders; 6 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Imigran 10 mg Nasal Spray, SolutionGlaxoSmithKline (Ireland) LimitedNational authorisation (PA)Marketed
Imigran Ftab 100 mg film-coated tabletsGlaxoSmithKline (Ireland) LimitedNational authorisation (PA)Marketed
Imigran Ftab 50 mg film-coated tabletsGlaxoSmithKline (Ireland) LimitedNational authorisation (PA)Marketed
SUMATRAN 100 mg tabletsRowex Limited,National authorisation (PA)Marketed
SUMATRAN 50 mg tabletsRowex Limited,National authorisation (PA)Marketed
Sumatran Relief 50mg tabletsRowex Limited,National authorisation (PA)Marketed
Imigran 20 mg nasal spray, solutionIMED Healthcare Ltd.Parallel import (PPA)Not stated
Imigran Ftab 50 mg film-coated tabletsIMED Healthcare Ltd.,Parallel import (PPA)Not stated

Other substances in ATC group N02CC

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 9 other active substances share the group N02CC with this product:

Zolmitriptan (6) · ELETRIPTAN (3) · Sumatriptan succinate (3) · Lasmiditan Succinate (3) · Frovatriptan succinate monohydrate (2) · Almotriptan (1) · FROVATRIPTAN (1) · Naproxen sodium (1) · Naratriptan (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

GlaxoSmithKline (Ireland) Limited holds 95 products on the HPRA list, with 63 different active substances; 77 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.